Penumbra [PEN] vs Bio-Rad Laboratories [BIO] Detailed Stock Comparison
Penumbra
NYSE
Loading...
Bio-Rad Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Penumbra wins in 8 metrics, Bio-Rad Laboratories wins in 11 metrics, with 0 ties. Bio-Rad Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Penumbra | Bio-Rad Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 67.16 | 25.78 | Bio-Rad Laboratories |
| Price-to-Book Ratio | 7.63 | 1.08 | Bio-Rad Laboratories |
| Debt-to-Equity Ratio | 17.04 | 19.73 | Penumbra |
| PEG Ratio | -0.39 | 24.52 | Penumbra |
| EV/EBITDA | 54.69 | 18.92 | Bio-Rad Laboratories |
| Profit Margin (TTM) | 11.54% | 12.50% | Bio-Rad Laboratories |
| Operating Margin (TTM) | 12.03% | 12.19% | Bio-Rad Laboratories |
| EBITDA Margin (TTM) | 12.03% | 12.19% | Bio-Rad Laboratories |
| Return on Equity | 12.03% | 4.59% | Penumbra |
| Return on Assets (TTM) | 6.20% | 1.59% | Penumbra |
| Free Cash Flow (TTM) | $147.30M | $266.20M | Bio-Rad Laboratories |
| 1-Year Return | 19.63% | -9.50% | Penumbra |
| Price-to-Sales Ratio (TTM) | 7.71 | 2.97 | Bio-Rad Laboratories |
| Enterprise Value | $9.67B | $7.76B | Penumbra |
| EV/Revenue Ratio | 7.55 | 3.04 | Bio-Rad Laboratories |
| Gross Profit Margin (TTM) | 65.99% | 52.99% | Penumbra |
| Revenue per Share (TTM) | $33 | $92 | Bio-Rad Laboratories |
| Earnings per Share (Diluted) | $3.77 | $11.08 | Bio-Rad Laboratories |
| Beta (Stock Volatility) | 0.40 | 0.91 | Penumbra |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Penumbra vs Bio-Rad Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Penumbra | 5.21% | -0.73% | 9.84% | -7.03% | -13.82% | 4.74% |
| Bio-Rad Laboratories | 6.59% | -0.76% | 16.70% | 25.02% | 1.77% | -12.61% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Penumbra | 19.63% | 51.55% | 13.77% | 508.64% | 508.64% | 508.64% |
| Bio-Rad Laboratories | -9.50% | -42.45% | -42.86% | 104.29% | 244.57% | 423.37% |
Performance & Financial Health Analysis: Penumbra vs Bio-Rad Laboratories
| Metric | PEN | BIO |
|---|---|---|
| Market Information | ||
| Market Cap | $9.87B | $7.59B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 333,680 | 246,810 |
| 90 Day Avg. Volume | 478,483 | 301,780 |
| Last Close | $264.47 | $303.80 |
| 52 Week Range | $184.80 - $310.00 | $211.43 - $387.99 |
| % from 52W High | -14.69% | -21.70% |
| All-Time High | $348.67 (Jun 26, 2023) | $832.70 (Aug 30, 2021) |
| % from All-Time High | -24.15% | -63.52% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.13% | 0.02% |
| Quarterly Earnings Growth | 0.13% | 0.02% |
| Financial Health | ||
| Profit Margin (TTM) | 0.12% | 0.13% |
| Operating Margin (TTM) | 0.12% | 0.12% |
| Return on Equity (TTM) | 0.12% | 0.05% |
| Debt to Equity (MRQ) | 17.04 | 19.73 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $33.20 | $263.42 |
| Cash per Share (MRQ) | $10.89 | $50.76 |
| Operating Cash Flow (TTM) | $201.49M | $534.20M |
| Levered Free Cash Flow (TTM) | $97.77M | $223.40M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Penumbra vs Bio-Rad Laboratories
| Metric | PEN | BIO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 67.16 | 25.78 |
| Forward P/E | 66.98 | 24.52 |
| PEG Ratio | -0.39 | 24.52 |
| Price to Sales (TTM) | 7.71 | 2.97 |
| Price to Book (MRQ) | 7.63 | 1.08 |
| Market Capitalization | ||
| Market Capitalization | $9.87B | $7.59B |
| Enterprise Value | $9.67B | $7.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.55 | 3.04 |
| Enterprise to EBITDA | 54.69 | 18.92 |
| Risk & Other Metrics | ||
| Beta | 0.40 | 0.91 |
| Book Value per Share (MRQ) | $33.20 | $263.42 |
Financial Statements Comparison: Penumbra vs Bio-Rad Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PEN | BIO |
|---|---|---|
| Revenue/Sales | $324.14M | $585.40M |
| Cost of Goods Sold | $108.26M | $279.40M |
| Gross Profit | $215.88M | $306.00M |
| Research & Development | $22.08M | $73.50M |
| Operating Income (EBIT) | $40.35M | $23.70M |
| EBITDA | $49.20M | $98.50M |
| Pre-Tax Income | $43.86M | $83.40M |
| Income Tax | $4.64M | $19.40M |
| Net Income (Profit) | $39.22M | $64.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PEN | BIO |
|---|---|---|
| Cash & Equivalents | $376.05M | $521.40M |
| Total Current Assets | $999.71M | $3.04B |
| Total Current Liabilities | $158.63M | $506.60M |
| Long-Term Debt | $205.85M | $1.33B |
| Total Shareholders Equity | $1.21B | $6.68B |
| Retained Earnings | $99.23M | $7.48B |
| Property, Plant & Equipment | $274.92M | $681.70M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PEN | BIO |
|---|---|---|
| Operating Cash Flow | $46.01M | $156.00M |
| Capital Expenditures | $-13.47M | $-34.40M |
| Free Cash Flow | $35.50M | $95.50M |
| Debt Repayment | $-613,000 | $-100,000 |
| Common Stock Repurchase | N/A | $-101.90M |
Short Interest & Institutional Ownership Analysis
| Metric | PEN | BIO |
|---|---|---|
| Shares Short | 1.52M | 917,109 |
| Short Ratio | 3.07 | 3.32 |
| Short % of Float | 0.05% | 0.05% |
| Average Daily Volume (10 Day) | 333,680 | 246,810 |
| Average Daily Volume (90 Day) | 478,483 | 301,780 |
| Shares Outstanding | 38.49M | 28.01M |
| Float Shares | 37.83M | 18.51M |
| % Held by Insiders | 0.04% | 0.16% |
| % Held by Institutions | 0.94% | 0.90% |
Dividend Analysis & Yield Comparison: Penumbra vs Bio-Rad Laboratories
| Metric | PEN | BIO |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |